 Pyrrolidinones
"Pyrrolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
| Descriptor ID |
D011760
|
| MeSH Number(s) |
D03.383.773.812
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidinones".
This graph shows the total number of publications written about "Pyrrolidinones" by people in this website by year, and whether "Pyrrolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2010 | 2 | 0 | 2 | | 2011 | 3 | 0 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2014 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrrolidinones" by people in Profiles.
-
Lauinger L, Li J, Shostak A, Cemel IA, Ha N, Zhang Y, Merkl PE, Obermeyer S, Stankovic-Valentin N, Schafmeier T, Wever WJ, Bowers AA, Carter KP, Palmer AE, Tschochner H, Melchior F, Deshaies RJ, Brunner M, Diernfellner A. Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases. Nat Chem Biol. 2017 Jul; 13(7):709-714.
-
Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings A. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014; 9(3):e90485.
-
Sharma A, Choudhury S, Nakade UP, Yadav RS, Garg SK. Calcium influx and release mechanism(s) in histamine-induced myometrial contraction in buffaloes. Anim Reprod Sci. 2014 May; 146(3-4):157-64.
-
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91.
-
Figueroa M, Raja H, Falkinham JO, Adcock AF, Kroll DJ, Wani MC, Pearce CJ, Oberlies NH. Peptaibols, tetramic acid derivatives, isocoumarins, and sesquiterpenes from a Bionectria sp. (MSX 47401). J Nat Prod. 2013 Jun 28; 76(6):1007-15.
-
Taiwo B, Matining RM, Zheng L, Lederman MM, Rinaldo CR, Kim PS, Berzins BI, Kuritzkes DR, Jennings A, Eron JJ, Wilson CC. Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother. 2013 Aug; 68(8):1857-61.
-
Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther. 2012; 17(7):1301-9.
-
Rasulev B, Turabekova M, Gorska M, Kulig K, Bielejewska A, Lipkowski J, Leszczynski J. Use of quantitative structure-enantioselective retention relationship for the liquid chromatography chiral separation prediction of the series of pyrrolidin-2-one compounds. Chirality. 2012 Jan; 24(1):72-7.
-
Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011 Nov 13; 25(17):2113-22.
-
Gardner EM, Melendez AG, Astiz M, Bray K. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):34-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|